Targeting Pdzrn3 maintains adult blood-brain barrier and central nervous system homeostasis

被引:8
|
作者
Gueniot, Florian [1 ]
Rubin, Sebastien [1 ]
Bougaran, Pauline [1 ]
Abelanet, Alice [1 ]
Morel, Jean Luc [2 ]
Bontempi, Bruno [2 ]
Proust, Carole [1 ]
Dufourcq, Pascale [1 ,3 ]
Couffinhal, Thierry [1 ,4 ]
Duplaa, Cecile [1 ]
机构
[1] Univ Bordeaux, Biol Cardiovasc Dis, U1034, Bordeaux, France
[2] Univ Bordeaux, IMN, CNRS, UMR 5293, Bordeaux, France
[3] CHU Bordeaux, Serv Biochim Clin, Bordeaux, France
[4] CHU Bordeaux, Serv Malad Cardiaques & Vasc, Bordeaux, France
关键词
Vascular cognitive impairment; blood brain barrier; vascular permeability; Wnt pathway; endothelial tight junction; ALZHEIMERS-DISEASE; NEUROVASCULAR UNIT; VASCULAR DEVELOPMENT; MOUSE MODEL; IMPAIRMENT; DISRUPTION; PHENOTYPE; BREAKDOWN; CNS;
D O I
10.1177/0271678X211048981
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Blood brain barrier (BBB) disruption is a critical component of the pathophysiology of cognitive impairment of vascular etiology (VCI) and associated with Alzheimer's disease (AD). The Wnt pathway plays a crucial role in BBB maintenance, but there is limited data on its role in cognitive pathologies. The E3 ubiquitin ligase PDZRN3 is a regulator of the Wnt pathway. In a murine model of VCI, overexpressing Pdzrn3 in endothelial cell (EC) exacerbated BBB hyperpermeability and accelerated cognitive decline. We extended these observations, in both VCI and AD models, showing that EC-specific depletion of Pdzrn3, reinforced the BBB, with a decrease in vascular permeability and a subsequent spare in cognitive decline. We found that in cerebral vessels, Pdzrn3 depletion protects against AD-induced Wnt target gene alterations and enhances endothelial tight junctional proteins. Our results provide evidence that Wnt signaling could be a molecular link regulating BBB integrity and cognitive decline under VCI and AD pathologies.
引用
收藏
页码:613 / 629
页数:17
相关论文
共 50 条
  • [11] Dual System for the Central Nervous System Targeting and Blood-Brain Barrier Transport of a Selective Prolyl Oligopeptidase Inhibitor
    Teixido, Meritxell
    Zurita, Esther
    Mendieta, Laura
    Oller-Salvia, Benjami
    Prades, Roger
    Tarrago, Teresa
    Giralt, Ernest
    BIOPOLYMERS, 2013, 100 (06) : 662 - 674
  • [12] An Overview on the Physiopathology of the Blood-Brain Barrier and the Lipid-Based Nanocarriers for Central Nervous System Delivery
    Susa, Francesca
    Arpicco, Silvia
    Pirri, Candido Fabrizio
    Limongi, Tania
    PHARMACEUTICS, 2024, 16 (07)
  • [13] Involvement of noncoding RNA in blood-brain barrier integrity in central nervous system disease
    Liu, Xi
    Shen, Ling
    Han, Bing
    Yao, Honghong
    NON-CODING RNA RESEARCH, 2021, 6 (03): : 130 - 138
  • [14] The "fate" of polymeric and lipid nanoparticles for brain delivery and targeting: Strategies and mechanism of blood-brain barrier crossing and trafficking into the central nervous system
    Tosi, Giovanni
    Musumeci, Teresa
    Ruozi, Barbara
    Carbone, Claudia
    Belletti, Daniela
    Pignatello, Rosario
    Vandelli, Maria Angela
    Puglisi, Giovanni
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2016, 32 : 66 - 76
  • [15] Flavonoids and the brain: Interactions at the blood-brain barrier and their physiological effects on the central nervous system
    Youdim, KA
    Shukitt-Hale, B
    Joseph, JA
    FREE RADICAL BIOLOGY AND MEDICINE, 2004, 37 (11) : 1683 - 1693
  • [16] Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning
    Morofuji, Yoichi
    Nakagawa, Shinsuke
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (13) : 1466 - 1485
  • [17] The blood-brain barrier and its role in immune privilege in the central nervous system
    Pachter, JS
    de Vries, HE
    Fabry, Z
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2003, 62 (06) : 593 - 604
  • [18] Nanotherapeutics engineered to cross the blood-brain barrier for advanced drug delivery to the central nervous system
    Kim, Jinhwan
    Ahn, Song Ih
    Kim, YongTae
    JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY, 2019, 73 : 8 - 18
  • [19] Interactions of Serum Amyloid A Proteins with the Blood-Brain Barrier: Implications for Central Nervous System Disease
    Erickson, Michelle A.
    Mahankali, Anvitha P.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)
  • [20] MicroRNAs in central nervous system diseases: A prospective role in regulating blood-brain barrier integrity
    Ma, Feifei
    Zhang, Xuejing
    Yin, Ke-Jie
    EXPERIMENTAL NEUROLOGY, 2020, 323